Utilization Patterns of Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus in Italy: A Retrospective Cohort Study
Open Access
- 1 April 2018
- journal article
- research article
- Published by Springer Science and Business Media LLC in Diabetes Therapy
- Vol. 9 (2), 789-801
- https://doi.org/10.1007/s13300-018-0396-2
Abstract
Introduction: Real-world evidence on glucagon-like peptide-1 receptor agonist (GLP-1 RAs) usage is emerging in different European countries but is lacking in Italy. This retrospective cohort study aimed to describe the real-world drug utilization patterns in patients initiating GLP-1 RAs for treating T2DM in Italy. Methods: Adults aged >= 20 years and with >= 1 oral antidiabetic drug (alone or in combination with insulin) other than GLP-1 RAs in the 6 months prior to initiating exenatide twice daily (exBID), exenatide once weekly (exQW), dulaglutide once weekly (DULA), liraglutide once daily (LIRA) or lixisenatide once daily (LIXI) between March and July 2016 were retrospectively identified in the Italian IMS LifeLink (TM) longitudinal prescriptions database (retail pharmacy data). Patients with >= 6-month follow-up (defined as evidence of any prescription activity) were included. Proportions of patients who remained persistent (continued treatment until discontinuation/switch) in the first 6 months and of those who discontinued or switched to a different GLP-1 RA over the entire follow-up were recorded. For each treatment, the average daily/weekly dosage (ADD/AWD) while persistent during the available follow-up was calculated. Results: We identified 7319 patients: 92 exBID, 970 exQW, 3368 DULA, 2573 LIRA and 316 LIXI. Across treatments, 89% patients were >= 50 years old, 54% were males, and the median follow-up duration ranged between 8.1 and 8.7 months. At 6 months, 35% exBID, 47% exQW, 62% DULA, 50% LIRA and 40% LIXI patients remained persistent. Over the entire follow-up, median persistence days varied from 73 (exBID) to >300 days (DULA). The mean +/- SD ADD/AWD was exBID: 17.7 +/- 2.1 mu g/day; exQW: 2.1 +/- 0.1 mg/week; DULA: 1.5 +/- 0.2 mg/week; LIRA: 1.5 +/- 0.2 mg/day; LIXI: 21.0 +/- 5.5 mu g/day. Conclusions: This real-world analysis suggests differences exist in persistence between patients treated with various GLP-1 RAs. Among the investigated treatments, patients prescribed exBID recorded the lowest and those prescribed DULA the highest persistence with therapy.Keywords
Funding Information
- Eli Lilly and Company
This publication has 22 references indexed in Scilit:
- Economic aspects in the management of diabetes in ItalyBMJ Open Diabetes Research & Care, 2016
- Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2)Diabetes Care, 2015
- Impact of Medication Adherence and Persistence on Clinical and Economic Outcomes in Patients with Type 2 Diabetes Treated with Liraglutide: A Retrospective Cohort StudyAdvances in Therapy, 2015
- Correlation Between Baseline Characteristics and Clinical Outcomes in a Large Population of Diabetes Patients Treated with Liraglutide in a Real-World Setting in ItalyClinical Therapeutics, 2015
- Estimating the real world daily usage and cost for exenatide twice daily and liraglutide in Germany, the Netherlands, and the UK based on volumes dispensed by pharmaciesClinicoEconomics and Outcomes Research, 2015
- Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of DiabetesDiabetes Care, 2014
- GLP-1 Receptor Agonists for Type 2 Diabetes Mellitus: Recent Developments and Emerging AgentsPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2014
- Exenatide BID and liraglutide QD treatment patterns among type 2 diabetes patients in GermanyJournal of Medical Economics, 2012
- Increased Persistency in Medication Use by U.S. Medicare Beneficiaries With Diabetes Is Associated With Lower Hospitalization Rates and Cost SavingsDiabetes Care, 2009
- Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: An analysis of third-party managed care claims dataClinical Therapeutics, 2006